These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 21667222)

  • 41. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens.
    Contin M; Alberghini L; Candela C; Benini G; Riva R
    Epilepsy Res; 2016 May; 122():79-83. PubMed ID: 26987080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.
    Kesselheim AS; Stedman MR; Bubrick EJ; Gagne JJ; Misono AS; Lee JL; Brookhart MA; Avorn J; Shrank WH
    Drugs; 2010 Mar; 70(5):605-21. PubMed ID: 20329806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Requirements for generic anti-epileptic medicines: a regulatory perspective.
    Maliepaard M; Hekster YA; Kappelle A; van Puijenbroek EP; Elferink AJ; Welink J; Gispen-de Wied CC; Lekkerkerker FJ
    J Neurol; 2009 Dec; 256(12):1966-71. PubMed ID: 19603244
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.
    LeLorier J; Duh MS; Paradis PE; Lefebvre P; Weiner J; Manjunath R; Sheehy O
    Neurology; 2008 May; 70(22 Pt 2):2179-86. PubMed ID: 18505997
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Bioequivalence and generics of index drugs with narrow therapeutic margins].
    Le Corre P
    Presse Med; 2010 Feb; 39(2):169-76. PubMed ID: 19932591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial.
    Privitera MD; Welty TE; Gidal BE; Diaz FJ; Krebill R; Szaflarski JP; Dworetzky BA; Pollard JR; Elder EJ; Jiang W; Jiang X; Berg M
    Lancet Neurol; 2016 Apr; 15(4):365-72. PubMed ID: 26875743
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.
    LeLorier J; Duh MS; Paradis PE; Latrémouille-Viau D; Lefebvre P; Manjunath R; Sheehy O
    Curr Med Res Opin; 2008 Apr; 24(4):1069-81. PubMed ID: 18315941
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Generic drugs: we must cut pharmaceutical spending but undertaking drug quality].
    Carrillo Norte JA; Postigo Mota S
    Rev Enferm; 2012 Feb; 35(2):10-9. PubMed ID: 22670381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Generic antiepileptic drugs and associated medical resource utilization in the United States.
    Labiner DM; Paradis PE; Manjunath R; Duh MS; Lafeuille MH; Latrémouille-Viau D; Lefebvre P; Helmers SL
    Neurology; 2010 May; 74(20):1566-74. PubMed ID: 20393142
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of generic medication in epilepsy: a review of potential issues and challenges.
    Van Paesschen W; Hauman H; Lagae L
    Eur J Paediatr Neurol; 2009 Mar; 13(2):87-92. PubMed ID: 18790656
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy.
    Erickson SC; Le L; Ramsey SD; Solow BK; Zakharyan A; Stockl KM; Harada AS; Curtis B
    Epilepsia; 2011 Jul; 52(7):1365-71. PubMed ID: 21692778
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Switching generic antiepileptic drug manufacturer not linked to seizures: A case-crossover study.
    Kesselheim AS; Bykov K; Gagne JJ; Wang SV; Choudhry NK
    Neurology; 2016 Oct; 87(17):1796-1801. PubMed ID: 27683844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies.
    Yamada M; Welty TE
    Ann Pharmacother; 2011 Nov; 45(11):1406-15. PubMed ID: 22028417
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Perron R
    Neurology; 2005 Apr; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15858865
    [No Abstract]   [Full Text] [Related]  

  • 56. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
    Zachry WM; Doan QD; Clewell JD; Smith BJ
    Epilepsia; 2009 Mar; 50(3):493-500. PubMed ID: 18616554
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting.
    Markoula S; Chatzistefanidis D; Gatzonis S; Siatouni A; Siarava E; Verentzioti A; Kyritsis AP; Patsalos PN
    Seizure; 2017 May; 48():1-6. PubMed ID: 28363098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lower phenytoin serum levels in persons switched from brand to generic phenytoin.
    Wiberg CC
    Neurology; 2005 Apr; 64(8):1485-6; author reply 1485-6; discussion 1485-6. PubMed ID: 15851759
    [No Abstract]   [Full Text] [Related]  

  • 59. On safety margin for drug interchangeability.
    Zheng J; Chow SC; Song F
    J Biopharm Stat; 2017; 27(2):293-307. PubMed ID: 27911675
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Generics of antiepileptic drugs].
    Maeder-Ingvar M; Foletti GB
    Rev Med Suisse; 2010 May; 6(247):907-9. PubMed ID: 20499577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.